Anti-Amyloid Immunotherapy Comparison

Anti-Amyloid Immunotherapy Comparison

Overview

Anti-Amyloid Immunotherapy Comparison

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Immunotherapy Comparison</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Abeta protofibrils</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>N-terminal truncated Abeta</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Conformational epitopes</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Aggregated Abeta</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Oligomers and plaques</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>FDA Status</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Full approval</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Full approval</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Withdrawn</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-E Rate (Treatment)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>24.0%</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>35.5%</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>25.0%</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>6.5%</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-H Rate (Treatment)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>17.3%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>31.4%</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>19.1%</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Description</td>
</tr>
<tr>
<td class="label">CDR-SB</td>
<td>Clinical Dementia Rating Sum of Boxes</td>
</tr>
<tr>
<td class="label">iADRS</td>
<td>Integrated Alzheimer's Disease Rating Scale</td>
</tr>
<tr>
<td class="label">ADAS-Cog</td>
<td>Alzheimer's Disease Assessment Scale-Cognitive</td>
</tr>
<tr>
<td class="label">MMSE</td>
<td>Mini-Mental State Examination</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>What It Measures</td>
</tr>
<tr>
<td class="label">Amyloid PET (SUVr)</td>
<td>Amyloid plaque burden</td>
</tr>
<tr>
<td class="label">CSF p-tau181</td>
<td>Tau pathology</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Brain glucose metabolism</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protofibrils</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>10 mg/kg q2w</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>CLARITY-AD</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>-0.45</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">FDA status</td>
<td>Approved</td>
</tr>
<tr>
<td class="label">Plaque removal</td>
<td>59 centiloids</td>
</tr>
</table>

Anti-amyloid immunotherapies represent the first disease-modifying treatments for Alzheimer's disease, targeting the accumulation of amyloid-beta (Abeta) plaques in the brain. This comparison matrix provides a comprehensive analysis of the major monoclonal antibody therapies that have reached late-stage clinical development, examining their mechanisms of action, clinical trial results, safety profiles, and practical considerations for clinical use.

Mechanism of Action Comparison

Monoclonal Antibodies vs Small Molecules

All FDA-approved anti-amyloid immunotherapies are monoclonal antibodies administered intravenously. They differ in their specific targets:

Target Specificity

The different targets reflect distinct hypotheses about the most toxic form of Aβ:

• Plaque-targeting: Gantenerumab, Donanemab
• Oligomer-targeting: Crenezumab, Aducanumab
• Protofibril-targeting: Lecanemab

Phase 3 Clinical Trial Results

Lecanemab (Leqembi)

• Trial: CLARITY-AD (Phase 3)
• Population: Early AD (MCI due to AD or mild AD dementia)
• Primary endpoint: CDR-SB change at 18 months
• Results: -0.45 vs placebo (p<0.001), 27% slowing of decline
• Amyloid reduction: 59 centiloids at 18 months
• FDA status: Full approval (January 2023)

Donanemab (Kisunla)

• Trial: TRAILBLAZER-ALZ 2 (Phase 3)
• Population: Early AD with low-medium tau
• Primary endpoint: iADRS change at 24 months
• Results: -4.2 vs placebo (p<0.001), 35% slowing in low-medium tau
• Amyloid reduction: Complete plaque removal in 52% of patients
• FDA status: Full approval (July 2024)

Aducanumab (Aduhelm)

• Trials: EMERGE (positive), ENGAGE (negative)
• Population: Early AD
• Primary endpoint: CDR-SB change at 78 weeks
• Results: EMERGE: -0.22 vs placebo (p=0.012); ENGAGE: not significant
• FDA status: Withdrawn from market (2024)
• Note: Accelerated approval withdrawn by manufacturer

Gantenerumab

• Trial: GRADUATE-1/2 (Phase 3)
• Population: Early AD
• Results: Did not meet primary endpoint (negative)
• Status: Development discontinued

Crenezumab

• Trial: CREAD (Phase 3)
• Population: Early AD
• Results: Did not meet primary endpoint (negative)
• Status: Development discontinued

SAR228810

• Trial: Phase 2
• Status: Development discontinued

FDA Status Summary

ARIA Incidence Rates

Amyloid-related imaging abnormalities (ARIA) are the major safety concern with anti-amyloid immunotherapies:

ARIA-E (Edema)

ARIA-H (Hemorrhage)

ARIA Management

• Monitoring: MRI at baseline, 5th dose, 7th dose, and as symptoms develop
• Symptom management: Hold dosing if symptomatic ARIA detected
• Risk factors: APOE ε4 carrier status, anticoagulation use

Dosing Protocols

Lecanemab (Leqembi)

• Dose: 10 mg/kg every 2 weeks
• Infusion time: Approximately 1 hour
• Premedication: Not required
• Dosing adjustments: None recommended

Donanemab (Kisunla)

• Dose: 350 mg every 4 weeks (after titration)
• Titration: 350 mg at weeks 0, 2, 4; then 1400 mg at week 8
• Infusion time: Approximately 30 minutes
• Dosing pause: Can be discontinued after achieving amyloid clearance

Efficacy Endpoints

Clinical Measures

Biomarker Measures

Patient Selection Criteria

Appropriate Patients

• Diagnosis: MCI due to AD or mild AD dementia
• Amyloid confirmation: Positive amyloid PET or CSF biomarker
• Tau staging: Low-medium tau for optimal response
• Age: Typically 50-85 years
• MMSE: Usually ≥20

Contraindications

• Anticoagulation: P2Y12 inhibitors, warfarin with INR>3
• Prior ARIA: History of ARIA with previous anti-amyloid therapy
• Active infection: Significant CNS infection
• Unstable medical conditions

Comparison Matrix Table

*iADRS endpoint

Cross-Linked Pages

• [diseases/alzheimers-disease] - Alzheimer's Disease
• [diseases/mci] - Mild Cognitive Impairment
• [biomarkers/amyloid-pet] - Amyloid PET
• [biomarkers/csf-biomarkers] - CSF Biomarkers
• [clinical-trials/clarity-ad] - CLARITY-AD Trial
• [clinical-trials/trailblazer-alz] - TRAILBLAZER-ALZ Trial

Summary

Anti-amyloid immunotherapies represent a paradigm shift in Alzheimer's disease treatment. Lecanemab and Donanemab have demonstrated clinically meaningful benefits in early AD, though both require careful patient selection and monitoring for ARIA. The field continues to evolve with combination approaches and next-generation therapies in development.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References